Edwards Lifesciences $39M Securities Settlement, Check If You Qualify — Patel v. Edwards Lifesciences Corp., No. 8:24-cv-02221-AH-KES

There’s $39 million waiting for investors who bought Edwards Lifesciences stock between February 6 and July 24, 2024. Edwards agreed to pay that amount to settle claims that it misled shareholders about the growth of its heart-valve business. You have until December 2, 2026, to file a claim.

Edwards Lifesciences Securities Settlement — Key Facts

Field	Details
Settlement Amount	$39,000,000 cash, deposited into escrow as the Settlement Fund
Claim Deadline	December 2, 2026
Who Qualifies	Anyone who purchased or otherwise acquired Edwards Lifesciences (NYSE: EW) common stock from February 6, 2024 through July 24, 2024, and was damaged
Estimated Payout	Approximately $0.66 per eligible share before fees and costs; roughly $0.49 per share after estimated maximum fees and expenses
Proof Required (Yes/No)	Yes — brokerage statements, trade confirmations, or a broker-certified transaction history
Settlement Status	Preliminarily approved August 3, 2026; Settlement Hearing scheduled
Court & Case Number	U.S. District Court, Central District of California, Southern Division — No. 8:24-cv-02221-AH-KES
Law Alleged	Securities Exchange Act Sections 10(b) and 20(a), SEC Rule 10b-5
Administrator	Kroll Settlement Administration
Official Claim Site	edwardslifesciencessecuritieslitigation.com
Last Updated	September 25, 2026

Who Is Edwards Lifesciences and Why Are They Being Sued for Securities Fraud?

Edwards Lifesciences makes artificial heart valves, and its transcatheter aortic valve replacement (TAVR) platform is the growth engine analysts and investors watch most closely. Lead Plaintiffs — two public pension funds — argue Edwards and CEO Bernard J. Zovighian told investors TAVR growth was on track when internal information allegedly told a different story, and that the stock was trading at an inflated price as a result. Edwards denies making any false or misleading statement and says it disclosed the risk that TAVR growth could slow.

What Did Edwards Lifesciences Do to Shareholders Between February and July 2024?

The lawsuit claims Edwards and Zovighian made materially false and misleading statements about TAVR’s growth prospects during the class period, artificially inflating the stock price. When Edwards revised its guidance and disclosed disappointing results on July 24, 2024, the stock dropped — the court’s damages expert estimated $24.17 per share of artificial inflation came out of the price the next trading day. A federal judge already ruled on part of this fight: in September 2025, the court let the core securities fraud claims against Edwards and Zovighian proceed, while dismissing similar claims against three other former executives entirely.

Cummins faced a comparable securities fraud theory over EPA emissions statements, and Celgene’s $239 million settlement used the same recognized-loss allocation method Edwards is using here.

Here’s the honest observation: Edwards isn’t admitting fault, and the court hasn’t ruled on the merits. This settlement exists because both sides decided a guaranteed $39 million beat the risk of trial, summary judgment, and appeal — for either side.

Who Qualifies for the Edwards Lifesciences Securities Settlement?

Here’s exactly how to know if this case includes you.

• Investors who purchased or otherwise acquired Edwards Lifesciences common stock any time from February 6, 2024, through July 24, 2024
• Anyone who held those shares through the close of trading on July 24, 2024, when the alleged inflation left the stock price
• Investors who bought and sold entirely within the class period, whose recognized loss is calculated separately based on their sale price
• Edwards’ own officers, directors, and their immediate family members are excluded, along with anyone who properly opts out

Investors Outside the United States — Are You Still Covered?

Yes. This settlement covers “all persons or entities” who bought Edwards common stock during the class period — there’s no residency requirement. If you’re an international investor who purchased EW shares on the NYSE during the window, you’re eligible the same as a U.S. resident.

That’s standard for federal securities class actions: eligibility runs on what stock you bought and when, not where you live.

Not sure if you qualify for the Edwards Lifesciences settlement? A free consultation with a securities fraud attorney can help you sort out edge cases — like shares held through an employer retirement plan — before the December 2 deadline.

How Much Can Edwards Lifesciences Securities Settlement Class Members Get?

Every claim gets a “Recognized Loss Amount” instead of a flat payout. If you sold your shares before July 24, 2024, your Recognized Loss Amount is $0 — the alleged inflation hadn’t left the stock yet. If you sold between July 25 and October 22, 2024, your loss is the smaller of $24.17 per share, the gap between your purchase price and the average closing price from July 25 through your sale date, or your actual purchase-to-sale loss. If you still held the stock as of October 22, 2024, your loss is capped at $24.17 or your purchase price minus $66.77, whichever is smaller.

Edwards Payout for Shares Sold During the 90-Day Window

Edwards Payout for Shares Still Held as of October 22, 2024

What LIFO Matching Means for Multiple Trades

If you bought and sold Edwards stock more than once, your trades are matched Last In, First Out — your most recent purchases get matched against your most recent sales first. The Net Settlement Fund (the $39 million minus court-approved fees, costs, and taxes) is then split pro rata based on everyone’s Recognized Loss Amount relative to the total. That’s why the notice can only estimate $0.66 per share before fees — nobody knows the final number until every claim is in.

Distributions under $10 don’t get sent at all — the notice specifically says amounts calculating below that are folded into other claimants’ payments. That’s a small detail, but it means very small trades in this class period may not net you anything.

How to File Your Edwards Lifesciences Settlement Claim

1. Go to edwardslifesciencessecuritieslitigation.com and download or complete the Claim Form online
2. Gather your trade records for every Edwards common stock purchase, acquisition, and sale from February 6, 2024 through October 22, 2024
3. List each transaction’s date, number of shares, and price — the Claims Administrator doesn’t have your brokerage records
4. Attach supporting documentation — trade confirmations or account statements
5. Submit online or mail it postmarked no later than December 2, 2026
6. Watch your email — Kroll Settlement Administration may follow up if information is missing

Takes about 20 minutes if your brokerage records are organized. ⚠️ 68 days left as of this writing — file at edwardslifesciencessecuritieslitigation.com well before December 2, 2026.

Should Edwards Lifesciences Class Members Opt Out or Object Before December 2, 2026?

What Opting Out of the Edwards Lifesciences Settlement Actually Means

Opting out means no payment from the $39 million fund, but you keep the right to sue Edwards separately over these same claims. Most investors shouldn’t opt out without talking to a securities attorney first, since going it alone against a company this size is a serious undertaking. Exclusion requests must be received by December 2, 2026, addressed to Edwards Lifesciences Securities Litigation, EXCLUSIONS, c/o Kroll Settlement Administration, PO Box 5014, New York, NY 10150-5014, and must include your share counts and transaction details.

How to Object to the Edwards Lifesciences Settlement

Objecting means staying in the class while telling the court you think the deal, the Plan of Allocation, or the attorneys’ fee request is unfair. Written objections must be filed with the Clerk of the U.S. District Court for the Central District of California and served on Lead Counsel and Edwards’ counsel, all by December 2, 2026. The Settlement Hearing is December 16, 2026, at 1:30 p.m. Pacific Time, before Judge Anne Hwang, Courtroom 9C of the Central District of California in Los Angeles.

Talk to a class action lawsuit attorney before December 2 if you’re considering either option.

Edwards Lifesciences Securities Settlement — Key Dates, 2026

Milestone	Date
Class Period Begins	February 6, 2024
Corrective Disclosure / Class Period Ends	July 24, 2024
Settlement Stipulation Signed	July 1, 2026
Preliminary Approval Granted	August 3, 2026
Lead Counsel’s Fee Motion Filed	By November 11, 2026
Claim, Exclusion & Objection Deadline	December 2, 2026
Settlement Hearing	December 16, 2026, 1:30 p.m. Pacific
Expected Payment Date	UNVERIFIED — payments follow final approval, any appeals, and completion of claims processing; no exact date set

Edwards Lifesciences Settlement — Frequently Asked Questions, No. 8:24-cv-02221-AH-KES

Do I need a lawyer to file an Edwards Lifesciences settlement claim?

 No. The Claim Form at edwardslifesciencessecuritieslitigation.com is designed to be filed without one, and Lead Counsel — Bernstein Litowitz Berger & Grossmann LLP — already represents the class on a contingency basis.

Is the Edwards Lifesciences settlement legitimate?

 Yes. It’s overseen by Judge Anne Hwang in the U.S. District Court for the Central District of California, case No. 8:24-cv-02221-AH-KES, and administered by Kroll Settlement Administration — a court-approved firm, not an unsolicited email.

When will Edwards Lifesciences settlement payments be sent?

 Only after the December 16, 2026 Settlement Hearing, final court approval, resolution of any appeals, and completion of claims processing. No exact payment date has been set.

What if I missed the Edwards Lifesciences claim deadline? 

If you miss December 2, 2026, you’ll be barred from receiving a payment, but you’ll still be bound by the settlement’s release of claims unless you separately excluded yourself by that same date.

Will my Edwards Lifesciences settlement payment be taxed?

 Possibly, though securities settlement payments are sometimes treated differently than ordinary income. Neither Edwards nor Class Counsel offers tax advice — check with a tax professional.

What if I sold my Edwards shares before July 24, 2024?

 Your Recognized Loss Amount is $0 under the Plan of Allocation. The alleged artificial inflation hadn’t been removed from the stock price yet, so the formula doesn’t attribute a loss to sales that happened before the corrective disclosure.

How much will I get from the Edwards Lifesciences settlement? 

It depends on your specific trades, using a Recognized Loss Amount formula rather than a flat per-share number. The notice’s $0.66-per-share estimate is only an average before legal fees — some claimants will get more, some less, and very small claims under $10 aren’t paid at all.

What specific claims does this settlement resolve?

 Claims under Section 10(b) and Rule 10b-5 against Edwards and CEO Bernard J. Zovighian, and Section 20(a) claims against Zovighian, tied to statements about TAVR growth prospects made between February 6 and July 24, 2024. Claims against three other former executives were dismissed earlier in the case and aren’t part of what you’re releasing.

Sources Used in This Edwards Lifesciences Securities Settlement Article

• Court-Authorized Notice of Pendency of Class Action and Proposed Settlement — Patel v. Edwards Lifesciences Corp., U.S. District Court, Central District of California, No. 8:24-cv-02221-AH-KES, dated August 24, 2026: https://devusscksastrapifa.blob.core.windows.net/logos/patelvedwards/blbg-4177862_v1_edwards_longnotice_formattedfinal.pdf
• Official Settlement Website — administered by Kroll Settlement Administration: http://www.edwardslifesciencessecuritieslitigation.com/

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against the court-authorized Notice of Pendency of Class Action and Proposed Settlement and the official settlement website administered by Kroll Settlement Administration, as of September 25, 2026. Last Updated: September 25, 2026.

This article is for informational purposes only and does not constitute legal advice. Laws vary by state and individual circumstances differ. For advice about your specific situation, consult a qualified attorney.